地舒单抗对日本类风湿关节炎预后亚组骨破坏的疗效:DRIVE II期研究
DRIVE研究为12个月多中心随机双盲安慰剂对照II期试验,纳入340例接受甲氨蝶呤的日本RA患者,随机接受安慰剂或地舒单抗60 mg每6、3、2个月一次。按RF、ACPA等风险因素分层的亚组分析显示,风险因素阳性患者中地舒单抗对12个月改良Sharp侵蚀评分变化的主终点结果总体一致,提示地舒单抗对RF阳性、ACPA阳性等风险因素患者可能有用。
要点
- 地舒单抗60 mg每2个月组在RF阳性者中侵蚀评分变化0.15(P=0.0010 vs 安慰剂)。
- 地舒单抗60 mg每2个月组在ACPA阳性者中侵蚀评分变化0.09(P<0.0001 vs 安慰剂)。
- 风险因素阳性患者中地舒单抗对骨侵蚀的疗效总体与主分析一致。
核心结论
- 地舒单抗对RF阳性、ACPA阳性及其他可能风险因素的RA患者是潜在有用的治疗选择。
研究设计与样本
- DRIVE研究为12个月、多中心、随机、双盲、安慰剂对照II期研究,纳入340例接受甲氨蝶呤的RA患者。
- 患者随机接受安慰剂或地舒单抗60 mg每6个月、每3个月或每2个月一次。
- 亚组分析涉及基线RF、ACPA、肿胀关节数、CRP水平、RA病程、ESR和糖皮质激素使用。
主要发现
- 按RF状态分层,安慰剂组RF阳性 vs 阴性亚组的侵蚀评分平均变化为1.18 vs 0.59。
- 按RF状态分层,每6个月组为0.25(P=0.0601 vs 安慰剂)vs 0.31(P=0.0827)。
- 按RF状态分层,每3个月组为0.21(P=0.0422)vs -0.02(P=0.0631)。
- 按RF状态分层,每2个月组为0.15(P=0.0010)vs -0.05(P=0.0332)。
- 按ACPA状态分层,安慰剂组ACPA阳性 vs 阴性亚组的侵蚀评分平均变化为1.30 vs 0.07。
关键数值与推荐
- 按ACPA状态分层,每6个月组为0.26(P=0.0142)vs 0.33(P=0.2748)。
- 按ACPA状态分层,每3个月组为0.16(P=0.0058)vs 0.08(P=0.7166)。
- 按ACPA状态分层,每2个月组为0.09(P<0.0001)vs 0.08(P=0.8939)。
临床怎么用
- 对于RF阳性、ACPA阳性等风险因素的RA患者,地舒单抗可作为抑制骨侵蚀的潜在治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the efficacy of denosumab for progressive bone erosion in risk factor subgroups of Japanese RA patients. METHODS: This study included 340 RA patients on MTX from the dose-response study of Denosumab in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE study-a 12-month, multicentre, randomized, double-blind, placebo-controlled, phase II study). The patients were randomized to receive placebo or denosumab 60 mg every 6 months, 3 months or 2 months. Subgroup analyses involved baseline RF, ACPA, swollen joint count, CRP level, RA duration, ESR and glucocorticoid use. RESULTS: Patients with risk factor positivity generally showed consistent results for the primary endpoint of the change in the modified Sharp erosion score at 12 months from baseline. In the placebo, every 6 months, every 3 months and every 2 months groups, the mean changes in the erosion score, according to the RF status (RF-positive vs -negative subgroups), were 1.18 vs 0.59, 0.25 (P = 0.0601 vs placebo) vs 0.31 (P = 0.0827), 0.21 (P = 0.0422) vs -0.02 (P = 0.0631) and 0.15 (P = 0.0010) vs -0.05 (P = 0.0332), respectively, while the mean changes in the erosion score, according to the ACPA status (ACPA-positive vs -negative subgroups), were 1.30 vs 0.07, 0.26 (P = 0.0142) vs 0.33 (P = 0.2748), 0.16 (P = 0.0058) vs 0.08 (P = 0.7166) and 0.09 (P < 0.0001) vs 0.08 (P = 0.8939), respectively. CONCLUSION: Denosumab is a potentially useful treatment option for RA patients who are positive for RF, ACPA and other possible risk factors. TRIAL REGISTRATION: JAPIC Clinical Trials Information, http://www.clinicaltrials.jp/user/cteSearch_e.jsp, JapicCTI-101263.
引用
- Ishiguro N, Tanaka Y, Yamanaka H, et al. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study. Rheumatology (Oxford). 2019. PMID: 30602032. doi:10.1093/rheumatology/key416
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。